RetroSense Therapeutics,(www.retro-sense.com) a privately-held biopharmaceutical company, today announced that Chief Executive Officer Sean Ainsworth will provide an update on the Company’s progress at the Biotech Showcase 2015 conference at 4:30 p.m. PST on Tuesday, January 13, 2015 at the Parc 55 Wyndham Hotel in San Francisco, CA. Recently designated with Orphan Drug Status, Retro-Sense’s lead product, RST-001 is being developed as a first-in-class gene therapy application of optogenetics designed to restore vision to those affected by retinal degenerative conditions.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
